Vaxxinity Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Mei Hu

İcra Kurulu Başkanı

US$1.4m

Toplam tazminat

CEO maaş yüzdesi	22.6%
CEO görev süresi	10.8yrs
CEO sahipliği	4.4%
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	3.2yrs

Son yönetim güncellemeleri

Recent updates

A Look At The Intrinsic Value Of Vaxxinity, Inc. (NASDAQ:VAXX)

Jan 08

Vaxxinity initiates rolling submission for its COVID-19 shot with UK's drug regulator

Sep 12

CEO Tazminat Analizi

Mei Hu'un ücretlendirmesi Vaxxinity'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Dec 31 2023	US$1m	US$308k	-US$57m
Sep 30 2023	n/a	n/a	-US$66m
Jun 30 2023	n/a	n/a	-US$72m
Mar 31 2023	n/a	n/a	-US$75m
Dec 31 2022	US$532k	US$400k	-US$75m
Sep 30 2022	n/a	n/a	-US$103m
Jun 30 2022	n/a	n/a	-US$114m
Mar 31 2022	n/a	n/a	-US$123m
Dec 31 2021	US$13m	US$400k	-US$137m
Sep 30 2021	n/a	n/a	-US$102m
Jun 30 2021	n/a	n/a	-US$88m
Mar 31 2021	n/a	n/a	-US$68m
Dec 31 2020	US$348k	US$335k	-US$40m

Tazminat ve Piyasa: Mei 'nin toplam tazminatı ($USD 1.36M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 654.40K ).

Tazminat ve Kazançlar: Mei şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Mei Hu (41 yo)

10.8yrs

Görev süresi

US$1,360,331

Tazminat

Ms. Mei Mei Hu, J.D., serves as Chief Executive Officer of Vaxxinity, Inc. and has been its President has been its Director since 2014 and served as its President until June 2022. She Co-Founded Vaxxinity,...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Louis Reese	Co-Founder & Executive Chairman of the Board	10.1yrs	US$1.29m	3.13% $ 7.9k
Mei Hu	Co-Founder	no data	US$1.36m	4.35% $ 11.0k
Sumita Ray	Chief Legal	less than a year	US$823.41k	Veri yok
Jason Pesile	Chief Accounting Officer	less than a year	Veri yok	Veri yok
Jean-Cosme Dodart	Chief Scientific Officer	less than a year	Veri yok	Veri yok
Mark Joinnides	Chief of Staff	no data	Veri yok	Veri yok
Manal Morsy	Chief Regulatory Officer	less than a year	Veri yok	Veri yok

0.8yrs

Ortalama Görev Süresi

46yo

Ortalama Yaş

Deneyimli Yönetim: VAXX 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Louis Reese	Co-Founder & Executive Chairman of the Board	10.1yrs	US$1.29m	3.13% $ 7.9k
Mei Hu	Co-Founder	10.8yrs	US$1.36m	4.35% $ 11.0k
George Hornig	Independent Director	2.8yrs	US$264.15k	0% $ 0
Peter Diamandis	Non-Employee Independent Director	3.6yrs	US$233.94k	1.59% $ 4.0k
Eric Reiman	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jeffrey Cummings	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Stanley Plotkin	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Gabrielle Toledano	Independent Director	1.7yrs	US$259.99k	0% $ 0
Richard Mohs	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Brad Boeve	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Nick Fox	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Landon Ogilvie	Lead Independent Director	1.7yrs	US$270.62k	0.026% $ 65.7

3.2yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: VAXX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.2 yıldır).

Vaxxinity Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Vaxxinity, Inc. Announces Resignation of Katherine Eade from the Board of Directors

High number of new directors

Vaxxinity, Inc. Announces Executive Changes

Vaxxinity, Inc. Announces Executive Changes

Non-Employee Independent Director exercised options to buy US$1.0m worth of stock.

Less than half of directors are independent

Recent updates

Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine

Vaxxinity Files Form 15

Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024

Vaxxinity, Inc. Receives A Notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Vaxxinity, Inc. Announces the Publication of Data from Multiple Non-Human Primate Studies

Vaxxinity, Inc. to Present Data from UB-312 Program in Parkinson's Disease at International Conference on Alzheimer's and Parkinson's Diseases and Related Neurolog Disorders

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Vaxxinity, Inc. Announces Resignation of Katherine Eade from the Board of Directors

New major risk - Financial position

High number of new directors

Vaxxinity, Inc. Announces Executive Changes

Vaxxinity, Inc. Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer's Disease

New minor risk - Financial position

Vaxxinity, Inc. Announces Executive Changes

Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson's Disease

Non-Employee Independent Director exercised options to buy US$1.0m worth of stock.

Less than half of directors are independent

Vaxxinity, Inc. Announces the Relocation of its Corporate Headquarters

A Look At The Intrinsic Value Of Vaxxinity, Inc. (NASDAQ:VAXX)

Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612

Price target decreased to US$13.50

Less than half of directors are independent

Price target decreased to US$13.50

Vaxxinity Completes Enrollment in Pivotal Phase 3 Clinical Trial of UB-612 COVID-19 Vaccine Heterologous Booster Candidate and Initiates Rolling Submission for Provisional Approval in Australia

Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine

Vaxxinity initiates rolling submission for its COVID-19 shot with UK's drug regulator

Vaxxinity's Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in Non Human Primates

Vaxxinity, Inc. Presents Preclinical Data on Tau Vaccine Candidates At the 2022 Alzheimer's Association International Conference

Less than half of directors are independent

The Coalition for Epidemic Preparedness Innovations to Co-Fund Vaxxinity, Inc.'s Pivotal Phase 3 UB-612 Heterologous Booster Trial to Combat SARS-CoV-2 variants

Less than half of directors are independent

Vaxxinity, Inc. Announces First Participant Dosed in Phase 3 Study of Next-Generation Covid-19 Vaccine Booster

Vaxxinity’s COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Other Variants of Concern

Vaxxinity, Inc. Announces First Parkinson’s Disease Patient Dosed in Part B of Phase 1 Clinical Trial of UB-312

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Non-Employee Independent Director recently bought US$63k worth of stock

Co-Founder & Executive Chairman recently bought US$242k worth of stock

Less than half of directors are independent

Second quarter 2021 earnings released: US$0.39 loss per share

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş